Results and lessons from the spironolactone to prevent cardiovascular events in early stage chronic kidney disease (STOP-CKD) randomised controlled trial

BMJ Open

Volumn 6, Issue 2, 2016, Pages

  Ng, Khai P ^a   Jain, Poorva ^b   Gill, Paramjit S ^b   Heer, Gurdip ^b   Townend, Jonathan N ^a   Freemantle, Nick ^c   Greenfield, Sheila ^b   McManus, Richard J ^d   Ferro, Charles J ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

ADULT; ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ELECTRONIC MEDICAL RECORD; FEMALE; GENERAL PRACTICE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNITED KINGDOM; AGED; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; ENGLAND; FEASIBILITY STUDY; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; ENGLAND; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 84960386411     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-010519     Document Type: Article

References (56)

1. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
2. Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006;17:2034-47.
3. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073-81.
4. Mafham M, Emberson J, Landray MJ, et al. Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis. PLoS ONE 2011;6:e25920.
5. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002;39(Suppl 1):S1-266.
6. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47.
7. Chue CD, Townend JN, Steeds RP, et al. Arterial stiffness in chronic kidney disease: causes and consequences. Heart 2010;96:817-23.
8. Moody WE, Edwards NC, Chue CD, et al. Arterial disease in chronic kidney disease. Heart 2013;99:365-72.
9. Guérin AP, Pannier B, Métivier F, et al. Assessment and significance of arterial stiffness in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 2008;17:635-41.
10. Blacher J, Guerin AP, Pannier B, et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999;99:2434-9.
11. Wang MC, Tsai WC, Chen JY, et al. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 2005;45:494-501.
12. Mourad JJ, Pannier B, Blacher J, et al. Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension. Kidney Int 2001;59:1834-41.
13. McMahon LP, Roger SD, Levin A. Development, prevention, and potential reversal of left ventricular hypertrophy in chronic kidney disease. J Am Soc Nephrol 2004;15:1640-7.
14. Edwards NC, Ferro CJ, Townend JN, et al. Aortic distensibility and arterial-ventricular coupling in early chronic kidney disease: a pattern resembling heart failure with preserved ejection fraction. Heart 2008;94:1038-43.
15. Balamuthusamy S, Srinivasan L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J 2008;155:791-805.
16. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:932-43.
17. Edwards NC, Ferro CJ, Kirkwood H, et al. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. Am J Cardiol 2010;106:1505-11.
18. Murphree DD, Thelen SM. Chronic kidney disease in primary care. J Am Board Fam Med 2010;23:542-50.
19. Richards N, Harris K, Whitfield M, et al. Primary care-based disease management of chronic kidney disease (CKD), based on estimated glomerular filtration rate (eGFR) reporting, improves patient outcomes. Nephrol Dial Transplant 2008;23:549-55.
20. Glassock RJ, Rule AD. The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli. Kidney Int 2012;82:270-7.
21. Glassock RJ, Winearls C. Ageing and the glomerular filtration rate: truths and consequences. Trans Am Clin Climatol Assoc 2009;120:419-28.
22. Ng KP, Jain P, Heer G, et al. Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial. Trials 2014;15:158.
23. Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 2009;20:2305-13.
24. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
25. National Institute for Health and Care Excellence. Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care (CG182). London: National Institute for Health and Care Excellence, 2014.
26. National Institute for Health & Clinical Excellence. Hypertension: clinical management for primary hypertension in adults [CG127]. London: National Institute for Health & Clinical Excellence, 2011.
27. Ng KP, Arnold J, Sharif A, et al. Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: a systematic review and meta-analysis of randomized trials. J Renin Angiotensin Aldosterone Syst 2015;16:599-613.
28. Hickson SS, Butlin M, Broad J, et al. Validity and repeatability of the Vicorder apparatus: a comparison with the SphygmoCor device. Hypertens Res 2009;32:1079-85.
29. Wright JM, Mattu GS, Perry TL Jr, et al. Validation of a new algorithm for the BPM-100 electronic oscillometric office blood pressure monitor. Blood Press Monit 2001;6:161-5.
30. Godwin M, Birtwhistle R, Delva D, etal. Manual and automated office measurements in relation to awake ambulatory blood pressure monitoring. Fam Pract 2011;28:110-17.
31. Edwards NC, Steeds RP, Stewart PM, etal. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 2009;54:505-12.
32. Taal MW. Chronic kidney disease in general populations and primary care: diagnostic and therapeutic considerations. CurrOpin Nephrol Hypertens 2013;22:593-8.
33. Sumi E, Teramukai S, Yamamoto K, etal. The correlation between the number of eligible patients in routine clinical practice and the low recruitment level in clinical trials: a retrospective study using electronic medical records. Trials 2013;14:426.
34. Jain P, Calvert M, Cockwell P, et al. The need for improved identification and accurate classification of stages 3-5 chronic kidney disease in primary care: retrospective cohort study. PLoS ONE 2014;9:e100831.
35. Health and Social Care Information Centre. Quality and Outcomes Framework (QOF)-2013-14. 2014. http://www.hscic.gov. uk/catalogue/PUB15751
36. Jameson K, Jick S, Hagberg KW, et al. Prevalence and management of chronic kidney disease in primary care patients in the UK. IntJ Clin Pract 2014;68:1110-21.
37. Health and Social Care Information Centre. Quality And Outcomes Framework, Achievement, Prevalence And Exceptions Data, 2011/12. 2012. http://www.hscic.gov. uk/catalogue/PUB08135/qof-11-12-rep.pdf
38. Stevens PE, O'Donoghue DJ, de Lusignan S, etal. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int 2007;72:92-9.
39. Zhang L, Wang F, Wang L, etal. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 2012;379:815-22.
40. Glassock RJ, Winearls C. An epidemic of chronic kidney disease: fact or fiction? Nephrol Dial Transplant 2008;23:1117-21.
41. Peterson JC, Adler S, Burkart JM, etal. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754-62.
42. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 2013;185:949-57.
43. Kovesdy CP, Bleyer AJ, Molnar MZ, etal. Blood pressure and mortality in U. S. veterans with chronic kidney disease: a cohort study. Ann Intern Med 2013;159:233-42.
44. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013;158:825-30.
45. National Institutes of Health. Landmark NIH study shows intensive blood pressure management may save live. 11 September 2015. http://www.nhlbi.nih.gov/news/press-releases/2015/landmark-nihstudy-shows-intensive-blood-pressure-management-may-save-lives
46. Hill NR, Lasserson D, Thompson B, et al. Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) triala multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2, 616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. Trials 2014;15:160.
47. Royal College of General Practitioners. Research Ready self accreditation. http://www.rcgp.org.uk/researchready
48. Royal College of General Practitioners. More than 1000 GP practices now 'Research Ready'. 27 January 2014. http://www.rcgp. org.uk/news/2014/january/more-than-1000-gp-practices-now-research-ready.aspx
49. NorthWestEHealth. FARSITE. http://nweh.co.uk/products/farsite
50. New JP, Bakerly ND, Leather D, et al. Obtaining real-world evidence: the Salford Lung Study. Thorax 2014;69:1152-4.
51. Treweek S, Pitkethly M, Cook J, et al. Strategies to improve recruitment to randomised controlled trials. Cochrane Database Syst Rev 2010; (4): MR000013.
52. Treweek S, Altman DG, Bower P, et al. Making randomised trials more efficient: report of the first meeting to discuss the Trial Forge platform. Trials 2015;16:261.
53. Campbell MK, Snowdon C, Francis D, etal. Recruitment to randomised trials: strategies for trial enrollment and participation study. The STEPS study. Health Technol Assess 2007;11:iii, ix-105.
54. Antoniou EE, Draper H, Reed K, et al. An empirical study on the preferred size of the participant information sheet in research. J Med Ethics 2011;37:557-62.
55. Plantinga LC, Tuot DS, Powe NR. Awareness of chronic kidney disease among patients and providers. Adv Chronic Kidney Dis 2010;17:225-36.
56. Caldwell PH, Hamilton S, Tan A, et al. Strategies for increasing recruitment to randomised controlled trials: systematic review. PLoS Med 2010;7:e1000368.